Literature DB >> 33775685

BBB-crossing adeno-associated virus vector: An excellent gene delivery tool for CNS disease treatment.

Wenli Chen1, Shun Yao2, Jie Wan3, Yu Tian4, Lan Huang4, Shanshan Wang5, Farhana Akter6, Yinqiu Wu7, Yizheng Yao8, Xiaochun Zhang9.   

Abstract

The presence of the blood-brain barrier (BBB) remains a challenge in the treatment of central nervous system (CNS) diseases, as it hinders the infiltration of many therapeutic drugs into the brain parenchyma. Therefore, developing efficacious pharmacological agents that can traverse the BBB is crucial for optimal treatment of diseases of the CNS such as neurodegenerative conditions and brain tumors. Adeno-associated virus (AAV), one of the most promising gene therapy vectors, has been shown to cross the BBB safely and is non-pathogenic in nature and therefore has been utilized for numerous diseases of the CNS. Along with the development of protein engineering techniques such as directed evolution including DNA shuffling, a great number of BBB-crossing AAVs have been developed, that could be systemically injected for therapeutic benefit. In this review, we discuss several feasible approaches to improve transportation of therapeutic agents to the CNS. We also discuss the advantages of using BBB-crossing AAVs, their role as a gene delivery agent and highlight the different types of BBB-AAV vectors that have been developed in order to provide a greater insight into how they can be used in diseases of the CNS.
Copyright © 2021. Published by Elsevier B.V.

Entities:  

Keywords:  Adeno-associated virus; BBB-crossing; Blood-brain barrier; CNS diseases; Gene therapy

Year:  2021        PMID: 33775685     DOI: 10.1016/j.jconrel.2021.03.029

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  6 in total

1.  Engineered AAVs for non-invasive gene delivery to rodent and non-human primate nervous systems.

Authors:  Xinhong Chen; Sripriya Ravindra Kumar; Cameron D Adams; Daping Yang; Tongtong Wang; Damien A Wolfe; Cynthia M Arokiaraj; Victoria Ngo; Lillian J Campos; Jessica A Griffiths; Takako Ichiki; Sarkis K Mazmanian; Peregrine B Osborne; Janet R Keast; Cory T Miller; Andrew S Fox; Isaac M Chiu; Viviana Gradinaru
Journal:  Neuron       Date:  2022-05-27       Impact factor: 18.688

2.  Evolution of drug delivery systems: From 1950 to 2020 and beyond.

Authors:  Haesun Park; Andrew Otte; Kinam Park
Journal:  J Control Release       Date:  2021-12-29       Impact factor: 11.467

Review 3.  Adeno-associated virus vector-mediated gene therapy for the treatment of ovarian cancer: a literature review.

Authors:  Jiaojiao Zhu; Tiansheng Qin; Linzhen Wei; Fan Chen; Yaoyao Ding; Qianqian Zhang; Yamei Dang
Journal:  Ann Transl Med       Date:  2022-09

Review 4.  Catching Them Early: Framework Parameters and Progress for Prenatal and Childhood Application of Advanced Therapies.

Authors:  Carsten W Lederer; Lola Koniali; Tina Buerki-Thurnherr; Panayiota L Papasavva; Stefania La Grutta; Amelia Licari; Frantisek Staud; Donato Bonifazi; Marina Kleanthous
Journal:  Pharmaceutics       Date:  2022-04-05       Impact factor: 6.525

Review 5.  Herbal medicine derived carbon dots: synthesis and applications in therapeutics, bioimaging and sensing.

Authors:  Wei-Kang Luo; Liang-Lin Zhang; Zhao-Yu Yang; Xiao-Hang Guo; Yao Wu; Wei Zhang; Jie-Kun Luo; Tao Tang; Yang Wang
Journal:  J Nanobiotechnology       Date:  2021-10-13       Impact factor: 10.435

Review 6.  Human Brain Organoid: A Versatile Tool for Modeling Neurodegeneration Diseases and for Drug Screening.

Authors:  Cuili Ma; Hwanwook Seong; Xiaowei Li; Xiao Yu; Shunliang Xu; Yujing Li
Journal:  Stem Cells Int       Date:  2022-08-25       Impact factor: 5.131

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.